Showing results (271-280 of 494) with videos related to
Sort By:
Pageof 50
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert CentresMonique K van der Kooij, Ellen Kapiteijn, Piotr Rutkowski, et al.European Journal of Cancer (Oxford, England : 1990)|March 24, 2018
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'Patrick Schöffski, Agnieszka Wozniak, Michael G Leahy, et al.Contemporary Oncology (Poznan, Poland)|July 7, 2025
Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitorsŁukasz Galus, Daria Tusień Małecka, Michał Michalak, et al.The Lancet. Oncology|July 23, 2013
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studySant Chawla, Robert Henshaw, Leanne Seeger, et al.Postepy Dermatologii I Alergologii|December 17, 2019
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre studyBożena Cybulska-Stopa, Iwona Ługowska, Paulina Jagodzińska-Mucha, et al.Annals of Surgical Oncology|May 29, 2014
Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary siteAleksandra Gos, Monika Jurkowska, Alexander van Akkooi, et al.The Lancet. Oncology|November 10, 2019
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 studySant Chawla, Jean-Yves Blay, Piotr Rutkowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trialsPiotr Rutkowski, Martine Van Glabbeke, Cathryn J Rankin, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 23, 2020
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practicePiotr Rutkowski, Marcin Ziętek, Bożena Cybulska-Stopa, et al.Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 31, 2007
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumorsPiotr Rutkowski, Maria Debiec-Rychter, Zbigniew I Nowecki, et al.Pageof 50